GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JBM (Healthcare) Ltd (HKSE:02161) » Definitions » Beta

JBM (Healthcare) (HKSE:02161) Beta : 0.32 (As of Apr. 06, 2025)


View and export this data going back to 2021. Start your Free Trial

What is JBM (Healthcare) Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2025-04-06), JBM (Healthcare)'s Beta is 0.32.


JBM (Healthcare) Beta Historical Data

The historical data trend for JBM (Healthcare)'s Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JBM (Healthcare) Beta Chart

JBM (Healthcare) Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Beta
Get a 7-Day Free Trial - - - - 0.82

JBM (Healthcare) Semi-Annual Data
Mar18 Mar19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.82 0.58

Competitive Comparison of JBM (Healthcare)'s Beta

For the Drug Manufacturers - Specialty & Generic subindustry, JBM (Healthcare)'s Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JBM (Healthcare)'s Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JBM (Healthcare)'s Beta distribution charts can be found below:

* The bar in red indicates where JBM (Healthcare)'s Beta falls into.


;
;

JBM (Healthcare) Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


JBM (Healthcare)  (HKSE:02161) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


JBM (Healthcare) Beta Related Terms

Thank you for viewing the detailed overview of JBM (Healthcare)'s Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


JBM (Healthcare) Business Description

Traded in Other Exchanges
N/A
Address
108 Wai Yip Street, Units 808-811, 8 floor, C-Bons International Centre, Kwun Tong, Kowloon, Hong Kong, HKG
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
Executives
Ubs Trustees (b.v.i.) Limited
Kingshill Development Group Inc
Sum Kwong Yip, Derek
Queenshill Development Limited
Lincoln's Hill Development Limited
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si
New Heritage Healthcare Limited 2101 Beneficial owner
Gavett Limited 2201 Interest of corporation controlled by you
United Islands Group Limited 2201 Interest of corporation controlled by you
Fortstar Limited 2201 Interest of corporation controlled by you
Tao Richard 2201 Interest of corporation controlled by you
Hon Hing Tong Patricia 2202 Interest of your spouse
Tao Paul 2201 Interest of corporation controlled by you
Choi Siu Ping 2202 Interest of your spouse
Longjin Investments Limited 2101 Beneficial owner

JBM (Healthcare) Headlines

No Headlines